We’re delighted to share that EpilepsyMeds received a Highly Commended award at the Excellence in Healthcare Partnership Awards 2026, recognising the strength and impact of the partnership behind the project.
The recognition reflects the close collaboration between Desitin Pharma, ChangeMed and Genetic Digital, and the way the solution was shaped by real-world clinical insight from the outset.
Multidisciplinary advisory boards were critical in identifying a genuine challenge faced by clinicians – navigating complex anti-seizure medicine information at the point of care, particularly around formulations, excipients and patient-specific needs.
Those insights directly informed the design, content and functionality of EpilepsyMeds, ensuring the final product addressed a real clinical problem and worked effectively in everyday practice. By combining pharmaceutical governance, clinical expertise and digital design, the partnership delivered a practical, trusted tool that supports safer, more confident clinical decision-making in epilepsy care.
It was a fantastic evening and a great moment to see the partnership recognised alongside such high-quality entries.